Sphera Funds Management LTD. Buys 33,427 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Sphera Funds Management LTD. lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 228,776 shares of the biopharmaceutical company's stock after purchasing an additional 33,427 shares during the period. Ultragenyx Pharmaceutical comprises approximately 1.7% of Sphera Funds Management LTD.'s investment portfolio, making the stock its 16th largest holding. Sphera Funds Management LTD. owned 0.25% of Ultragenyx Pharmaceutical worth $9,625,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in RARE. Smartleaf Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $35,000. Human Investing LLC bought a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $42,000. Van ECK Associates Corp raised its stake in Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 273 shares during the period. Finally, Quarry LP bought a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $84,000. 97.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on RARE shares. HC Wainwright restated a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Morgan Stanley boosted their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. JPMorgan Chase & Co. lifted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Piper Sandler reduced their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $90.93.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares in the company, valued at $2,116,156.50. The trade was a 1.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at $2,358,014.08. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Trading Up 1.6%

Shares of NASDAQ RARE traded up $0.58 during midday trading on Monday, hitting $36.19. 675,957 shares of the company's stock were exchanged, compared to its average volume of 825,606. Ultragenyx Pharmaceutical Inc. has a 12-month low of $29.59 and a 12-month high of $60.37. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -5.71 and a beta of 0.34. The business's fifty day moving average price is $36.31 and its two-hundred day moving average price is $41.53.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same period in the previous year, the firm posted ($2.03) EPS. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.